• Skip to primary navigation
  • Skip to main content
  • Skip to footer

chILD Foundation

Children's Interstitial Lung Disease - ChILD Foundation

DONATE JOIN US
  • What is Child
    • Overview
    • chILD Disorders
    • Steps in Diagnosis
    • Find a Specialist
  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Committee
    • Our Partners
    • Financials and Governance
    • chILD News
  • How You Can Help
    • Overview
    • Ways of Giving
  • Research
    • Overview
    • Current Funded Research
    • Physician Resources
  • Family Support
    • Overview
    • Living with chILD
    • Children’s Stories
    • chILD Events
    • Educational Materials
    • Forum
  • Contact
Home / Archives for Clinical Trials

Clinical Trials

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Boehringer Ingelheim

Boehringer Ingelheim announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).

Footer

DONATE JOIN US
  • What is chILD?
  • About Us
  • How You Can Help
  • Research
  • Family Support
  • Contact
  • Search
  • Helpful Links
  • 501(c)3 Status
  • Privacy Policy
©2021 chILD Foundation. All rights reserved worldwide. The chILD Foundation is a qualified 501(c)(3) tax-exempt organization.
Site managed by Nustart Solutions